Cibus (CBUS) Assets Average (2017 - 2026)
Cibus (CBUS) posted Assets Average of $317.6 million for Q4 2025, down 6.08% sequentially from $338.2 million in Q3 2025, and down 11.51% YoY from $359.0 million in Q4 2024.
Cibus (CBUS) Assets Average (2017 - 2026) Analysis & Trends
Cibus has reported Assets Average for 9 years, with the latest figure at $317.6 million in Q4 2025.
- Quarterly Assets Average fell 11.51% year-over-year to $317.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $317.6 million (down 11.51% YoY) and the FY2025 annual result came in at $327.6 million, down 26.76% from the prior year.
- Assets Average declined to $317.6 million in Q4 2025 per CBUS's latest filing, from $338.2 million in the prior quarter.
- Over five years, Assets Average peaked at $805.3 million in Q3 2023 and troughed at $21.4 million in Q1 2023.
- A 5-year average of $273.6 million and a median of $327.9 million in 2025 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2024: Assets Average surged 2642.73% in 2023, then sank 46.45% in 2024.
- Over 5 years, Assets Average stood at $38.4 million in 2021, then plunged by 35.97% to $24.6 million in 2022, then jumped by 2629.16% to $670.3 million in 2023, then tumbled by 46.45% to $359.0 million in 2024, then retreated by 11.51% to $317.6 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $317.6 million, $338.2 million, and $340.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Cibus | 131.25 Mn | 110.82 Mn | - | 309.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 309.25 Mn |
| Dec 31, 2025 | 317.64 Mn |
| Sep 30, 2025 | 338.21 Mn |
| Jun 30, 2025 | 340.62 Mn |
| Mar 31, 2025 | 342.56 Mn |
| Dec 31, 2024 | 358.97 Mn |
| Sep 30, 2024 | 460.63 Mn |
| Jun 30, 2024 | 543.21 Mn |
| Mar 31, 2024 | 538.72 Mn |
| Dec 31, 2023 | 670.32 Mn |
| Sep 30, 2023 | 805.25 Mn |
| Jun 30, 2023 | 417.28 Mn |
| Mar 31, 2023 | 21.35 Mn |
| Dec 31, 2022 | 24.56 Mn |
| Sep 30, 2022 | 29.36 Mn |
| Jun 30, 2022 | 35.18 Mn |
| Mar 31, 2022 | 37.77 Mn |
| Dec 31, 2021 | 38.36 Mn |
| Sep 30, 2021 | 43.65 Mn |
| Jun 30, 2021 | 50.10 Mn |